Hamas has demonstrated that it uses building materials for attack tunnels and underground lairs, not schools, homes, and hospitals
What happened when a bunch of kids took over America’s second-largest burger chain
Before they can be sent home, they need to be housed, fed, and given court dates
The average American spends more time per day on Facebook than on pet care
Cynk had no assets and no revenue. But it got a $6 billion valuation. Then it blew up
The check-in app is now a search app, and its logo has changed accordingly
The company saw 11 percent growth in earned premiums, and it's now the No. 2 auto insurer behind State Farm
Judy Olian offers nine ideas to boost the number of women and other minorities on b-school faculty
For chief executive officers, correlation between pay and stock performance is pretty random, as this chart illustrates
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."